BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 29, 2013
View Archived Issues
A prognostic peptide-based signature for end-stage renal disease in fetal urinary output
Read More
Medimmune to acquire Amplimmune
Read More
AiCuris presents a novel class of antibacterial compound with potent activity
Read More
An oral multikinase inhibitor shows potent antiangiogenic activity in vivo
Read More
Carolus and TAP seek to validate RANTES:Pf-4 as CT-2009 target
Read More
Acucela's SEATTLE study reaches half way enrollment
Read More
TRPM8 blockade as a potential new treatment strategy for urinary bladder disorders
Read More
Licensing and codevelopment agreement for NovaBiotics' first-in-class antifungal peptide
Read More
Lee's Pharmaceutical submits CTA to expand the APEX study to China
Read More
Orexo updates on OX-51 phase II dose-finding study
Read More
Arena Pharmaceuticals completes phase Ib APD-811 trial
Read More
FDA accepts for review dabigatran supplemental NDA
Read More
U.K.'s NICE does not recommend everolimus use by NHS
Read More
Cepheid's Xpert MTB/RIF test categorized by FDA
Read More
The University of Virgina presents new sphingosine kinase inhibitors
Read More
Novel EGFR inhibitors disclosed by Taiho Pharmaceutical
Read More
Scientists at Innate Pharma divulge new MAbs for cancer
Read More
Sunovion Pharmaceuticals discloses new antipsychotic agents
Read More
FDA extends PDUFA goal date for Xiaflex
Read More
Teva decides not to license RX-3117 from Rexahn
Read More
Japanese launch for Bonviva injection
Read More
Phase II trial planned for CF-102 in hepatocellular carcinoma
Read More
Daiichi Sankyo files marketing application for Ranmark in Japan
Read More
Grifols and Aradigm close worldwide licensing agreement for inhaled formulations of ciprofloxacin
Read More
Europe Commission approves Eylea for visual impairment complications following CRVO
Read More